Lung Cancer
Volume 70, Issue 2 , Pages 200-204 , November 2010

Histology classification is not a predictor of clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine or gemcitabine combinations

  • L. Trani

      Affiliations

    • Department of Experimental Medicine, “La Sapienza” University of Rome, Viale Regina Elena 324, 00161 Rome, Italy
    • ,
  • J. Myerson

      Affiliations

    • Lung Unit, The Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom
    • ,
  • S. Ashley

      Affiliations

    • Lung Unit, The Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom
    • ,
  • K. Young

      Affiliations

    • Lung Unit, The Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom
    • ,
  • A. Sheri

      Affiliations

    • Lung Unit, The Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom
    • ,
  • R. Hubner

      Affiliations

    • Lung Unit, The Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom
    • ,
  • M. Puglisi

      Affiliations

    • Department of Experimental Medicine, “La Sapienza” University of Rome, Viale Regina Elena 324, 00161 Rome, Italy
    • ,
  • S. Popat

      Affiliations

    • Lung Unit, The Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom
    • ,
  • M.E.R. O’Brien

      Affiliations

    • Lung Unit, The Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom
    • Corresponding Author InformationCorresponding author at: Royal Marsden Hospital, Department of Medicine, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom. Tel.: +44 2086613278; fax: +44 2086430373.

Received 7 December 2009 ,Revised 1 February 2010 ,Accepted 6 February 2010.

References 

  1. Novello S, Le Chevalier T. Chemotherapy for non-small cell lung cancer. Part 1. Early-stage disease. Oncology (Williston Park). 2003;17:357–364
  2. NSCLC Meta-Analysis Collaborative GroupSocinski MA, Crowell R, Hensing TE. Chemotherapy in addition to supportive care improves survival in advanced non-small cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26:4617–4625
  3. Langer CJ, Lilenbaum R, Sandler AB, Morris D. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:277S–289S
  4. D’Addario G, Felip E. ESMO guidelines working group non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19(Suppl. 2):pii39–pii40
  5. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for NSCLC. V.2.2008.
  6. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel–carboplatin alone or with bevacizumab in non-small cell lung cancer. NEJM. 2006;355:2542–2550
  7. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, et al. Cetuximab plus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) (FLEX); an open-label randomised phase III trial. Lancet. 2009;373(May (9674)):1525–1531
  8. Johnson DH, Chang AY, Ettinger DS, Kim KM, Bonomi P. Prognostic factors in advanced non-small cell lung cancer (NSCLC): analysis of eastern cooperative oncology group (ECOG) trials from 1981–1992. Proc Am Soc Clin Oncol. 1998;17:461a
  9. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002;122:1037–1057
  10. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543–3551
  11. Einhorn L. First-line chemotherapy for non-small-cell lung cancer: is there a superior regimen based on histology?. J Clin Oncol. 2008;26:3485–3486
  12. Hirsch FR, Spreafico A, Novello S, Wood MD, Simms L, Papotti M. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol. 2008;3:1468–1481
  13. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133–144
  14. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial). J Clin Oncol. 2003;21:2237–2246
  15. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol. 2005;23:2556–2568
  16. Giaccone G, Gallegos Ruiz M, Le Chevalier T, Thatcher N, Smit E, Rodriguez JA, et al. A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer. J Clin Oncol. 2005;23(16 suppl.):638s
  17. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, et al. Correlation of molecular markers including mutations with clinical outcomes in advanced non small cell lung cancer (NSCLC) patients (pts) treated with gefitinib, chemotherapy or chemotherapy and gefitinib in IDEAL and INTACT clinical trials. J Clin Oncol. 2005;23(16 suppl.):622s
  18. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527–1537
  19. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previous treated non-small cell lung cancer. NEJM. 2005;353:123–132
  20. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004 May 1;22(9):1589–1597
  21. Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist. 2009;14(March (3)):253–263
  22. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New guidelines to evaluate response to treatment in solid tumours (RECIST guidelines). J Natl Cancer Inst. 2000;92:205–216
  23. Tan E. Subset analysis of a phase III trial comparing two platinum-based doublets: i.v./oral vinorelbine (NVB) vs. docetaxel (DTX): impact of histology on response and survival in advanced non-small cell lung cancer (NSCLC). In: ECCO 15–34th ESMO Congress. Berlin, September. 2009;[abstract P-9078]
  24. Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009;27(July (19)):3217–3224
  25. Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, et al. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial. J Thorac Oncol. 2009;4(December (12)):1568–1571
  26. Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA. 2004;292:470–48427
  27. Sederholm C, Hillerdal G, Lamberg K, Kölbeck K, Dufmats M, Westberg R, et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: The Swedish Lung Cancer Study Group. J Clin Oncol. 2005;23:8380–8388
  28. Charloux A, Hedelin G, Dietemann A. Prognostic value of histology in patients with non-small cell lung cancer. Lung Cancer. 1997;17:123–134
  29. Sculier JP, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P. The impact of additional prognostic factors on survival and their relationship with anatomical extent of disease expressed by the 6th edition of the TNM classification of Malignant Tumors and the proposals for 7th edition. J Thorac Oncol. 2008 May;3(5):457–466

PII: S0169-5002(10)00068-1

doi: 10.1016/j.lungcan.2010.02.003

Lung Cancer
Volume 70, Issue 2 , Pages 200-204 , November 2010

Article Tools

* Image Usage & Resolution